Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 adaptive open-label multiple-dose trial of PF-06730512 in adults with focal segmental glomerulosclerosis (FSGS)
jRCT2021200032Phase 2Completed
- Sponsor
- Pfizer
- Start
- May 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label trial of PF-06730512 in focal segmental glomerulosclerosis (FSGS) (2 cohorts), sponsored by Pfizer. Primary endpoint: Percentage change from baseline in urinary protein-to-creatinine ratio (UPCR) based on 24-hour urine collection at Week 13. Started May 2021; status: completed.
02
Drugs
PF-06730512
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on jRCT2021200032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021200032.